Heart Failure Doesn't Mean Your Heart Has Stopped — Here's What It Really Means

Cardiology · 6 · March 5, 2026

The term "heart failure" is one of the worst names in medicine. It makes patients think their heart is about to stop. It's not. Heart failure means the heart can't pump blood efficiently enough to meet the body's demands. It's a chronic condition — not a death sentence. And the treatments available today are genuinely remarkable.

Two Types: HFrEF and HFpEF

Heart failure with reduced ejection fraction (HFrEF) means the heart muscle has weakened and can't squeeze forcefully enough. Ejection fraction — the percentage of blood ejected with each beat — is below 40% (normal is 55-70%). This typically results from heart attacks that damaged the muscle, long-standing high blood pressure, or dilated cardiomyopathy.

Heart failure with preserved ejection fraction (HFpEF) is the other half. The heart squeezes fine, but it's stiff and can't relax properly to fill with blood. Ejection fraction is 50% or above, yet the patient still has symptoms — shortness of breath, fatigue, fluid retention. HFpEF now accounts for over half of all heart failure cases and is especially common in older women with hypertension and obesity.

The Symptoms Are Gradual — That's the Problem

Heart failure doesn't usually announce itself dramatically. It creeps. You notice you're more breathless climbing stairs. Your shoes feel tighter in the evening because your ankles are swelling. You need an extra pillow to sleep comfortably. You gain 3 pounds in 2 days — that's fluid, not fat.

The New York Heart Association (NYHA) classification system grades severity from I to IV. Class I means you have structural heart disease but no symptoms during ordinary activity. Class IV means symptoms at rest. Most people are diagnosed at Class II or III, meaning they've already adapted to limitations they didn't realize were abnormal.

Treatment for HFrEF: The Four Pillars

Modern treatment for HFrEF is built on four medication classes that each independently reduce mortality. Together, they're called guideline-directed medical therapy (GDMT):

When all four are optimized, the cumulative mortality reduction exceeds 60% compared to no treatment. That's extraordinary. But a 2024 analysis in JAMA Cardiology found that only 1.2% of eligible patients were on all four medications at target doses. Most were undertreated. If you have HFrEF, ask your cardiologist specifically about each of these four classes.

Treatment for HFpEF: Finally Making Progress

HFpEF was called the "unmet need" of cardiology for years because nothing worked. That changed. The EMPEROR-Preserved trial showed empagliflozin reduced heart failure hospitalizations by 29% in HFpEF. Weight loss (through GLP-1 agonists like semaglutide) is now being studied with early results showing improved symptoms and exercise capacity in the STEP-HFpEF trial.

Key Takeaways

- Heart failure means the heart is struggling to pump efficiently — it hasn't stopped and won't necessarily stop

- Four medication classes each independently reduce mortality in HFrEF — combined reduction exceeds 60%

- Only 1.2% of eligible patients are on all four medications at target doses — most are undertreated

- SGLT2 inhibitors (dapagliflozin, empagliflozin) work for both HFrEF and HFpEF — a major recent advance

- Daily weight monitoring catches fluid retention early — gain of 2+ lbs in 24 hours should trigger a call to your doctor

Monitor your daily vitals, weight trends, and medication schedule with our integrated health dashboard.